Age, Race, Education Most Prevalent Disparities Tied to Menopausal Hormone Therapy Rx
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 27, 2023 -- Age, race, and education are the most prevalent disparities associated with menopausal hormone therapy (MHT) prescribing, according to research presented at the annual meeting of the North American Menopause Society, held from Sept. 27 to 30 in Philadelphia.
Danette Conklin, Ph.D., from University Hospitals in Cleveland, and colleagues conducted a scoping review of real-world studies to examine health care disparities in MHT prescribing based on demographic or clinical characteristics. The scoping review included 20 studies conducted from 1973 through 2015.
The researchers found that age, race, and education were the three most prevalent disparities associated with MHT. In 13 studies, age was associated with MHT disparities, with older women being prescribed, using, or being counseled on MHT more often than younger women in seven studies. In four studies, older women were prescribed, used, or were counseled on MHT less than younger women, while mixed results were seen in one study. Ten studies reported race disparities; all reported that Black women used, were prescribed, or were counseled less than their White, Mexican, Latina, or Asian counterparts. Compared with all other races, White women received/used MHT more often, with the exception of vaginal estrogen, which was prescribed to White women less than Hispanic menopausal women in one study. Six studies demonstrated educational disparities, with menopausal women with less versus more education counseled less and using or prescribed less MHT.
"This study reinforces that health care professionals must ask patients about their specific menopause symptoms so they can discuss the options that could help them improve their quality of life," Stephanie Faubion, M.D., medical director of the North American Menopause Society, said in a statement. "Black women should have the same access as White women to the available treatment options."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Risk for Most Cardiovascular Diseases No Higher With Inflammatory Bowel Disease
FRIDAY, May 3, 2024 -- Among postmenopausal women with inflammatory bowel disease (IBD), there is no higher risk for cardiovascular disease (CVD) compared with women without IBD...
Long-Term Study of Postmenopausal Women Does Not Support Many Preventive Therapies
THURSDAY, May 2, 2024 -- The longitudinal Women's Health Initiative trials do not support hormone therapy for cardiovascular disease prevention, calcium and vitamin D...
Menopausal Hormone Therapy Use Beyond 65 Years Beneficial
TUESDAY, April 16, 2024 -- Use of menopausal hormone therapy beyond age 65 years is associated with risk reductions in mortality as well as specific cancers and cardiovascular...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.